Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...